Latest Balance Sheet News

Control Bionics has successfully raised $0.6 million through a shortfall placement, reinforcing investor confidence as it accelerates commercialisation of its neurotechnology in assistive communication and emerging sports markets.

Australian Clinical Labs has announced a 12-month on-market share buy-back program targeting up to 10% of its shares, aiming to enhance shareholder returns without compromising its financial strength.

Dreadnought Resources reported a cash outflow in Q3 2025 driven by exploration spending but significantly strengthened its balance sheet with an $18 million capital raise post-quarter.

Northern Star Resources reported steady gold production and disciplined costs in Q1 FY26, with the KCGM Mill Expansion project progressing on schedule for early FY27 commissioning. Despite minor operational disruptions, the company maintains its full-year guidance and a robust financial position.

Bellevue Gold Limited reported robust cash flow for the September quarter, enabling a substantial early repayment on its project loan and maintaining a strong cash position.

Regis Resources reported a solid September quarter with 90.4koz gold production and a $158 million increase in cash and bullion. Key underground projects at Garden Well Main and Rosemont Stage 3 began ore production, supporting steady FY26 guidance.

Heartland Group Holdings reported a solid first quarter for FY2026, with improved profitability, stable costs, and accelerated realisation of non-strategic assets surpassing expectations.

Torque Metals reports breakthrough drilling results at its Paris Gold Project, extending high-grade gold mineralisation beyond existing resources and maintaining strong financial footing for ongoing exploration.

Kula Gold reports a maiden inferred tailings resource at Mt Palmer, confirms a significant niobium anomaly in Malawi, and completes a $2.5 million strategic placement to Forrestania Resources.

GR Engineering Services Limited reported a robust FY25 with revenue climbing to $479 million and EBITDA surging to $57.2 million, supported by successful project completions and an expanded contract pipeline. The company declared a higher fully franked dividend and maintains a strong cash position as it looks ahead to FY26.

Sigma Healthcare’s transformative merger with Chemist Warehouse has propelled the company into Australia’s top 20 ASX firms, with FY25 results exceeding expectations and synergy targets nearly doubling.

Michael Hill International reported flat earnings in FY25 amid inflation and subdued demand, while new CEO Jonathan Waecker outlines a strategy focused on innovation, AI integration, and margin recovery heading into FY26.